MX2020012292A - Compuestos para el tratamiento de cáncer de pancreas. - Google Patents

Compuestos para el tratamiento de cáncer de pancreas.

Info

Publication number
MX2020012292A
MX2020012292A MX2020012292A MX2020012292A MX2020012292A MX 2020012292 A MX2020012292 A MX 2020012292A MX 2020012292 A MX2020012292 A MX 2020012292A MX 2020012292 A MX2020012292 A MX 2020012292A MX 2020012292 A MX2020012292 A MX 2020012292A
Authority
MX
Mexico
Prior art keywords
pancreatic cancer
compounds
treatment
formula
therapeutically effective
Prior art date
Application number
MX2020012292A
Other languages
English (en)
Spanish (es)
Inventor
Wei Li
Miller Duane D
Wang Qinghui
Subhash Chauhan
Vivek Kumar Kashyap
Original Assignee
Univ Tennessee Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tennessee Res Found filed Critical Univ Tennessee Res Found
Publication of MX2020012292A publication Critical patent/MX2020012292A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41681,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
MX2020012292A 2018-05-15 2019-05-15 Compuestos para el tratamiento de cáncer de pancreas. MX2020012292A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862671833P 2018-05-15 2018-05-15
PCT/US2019/032476 WO2019222392A1 (en) 2018-05-15 2019-05-15 Compounds for treatment of pancreatic cancer

Publications (1)

Publication Number Publication Date
MX2020012292A true MX2020012292A (es) 2021-03-29

Family

ID=68541005

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020012292A MX2020012292A (es) 2018-05-15 2019-05-15 Compuestos para el tratamiento de cáncer de pancreas.

Country Status (9)

Country Link
US (1) US20190374512A1 (https=)
EP (1) EP3793548A4 (https=)
JP (1) JP2021523915A (https=)
KR (1) KR20210021982A (https=)
CN (1) CN112437664A (https=)
AU (1) AU2019270091A1 (https=)
CA (1) CA3099922A1 (https=)
MX (1) MX2020012292A (https=)
WO (1) WO2019222392A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20230413A1 (es) * 2020-04-03 2023-03-07 Veru Inc Metodos de tratamiento del coronavirus
CA3215936A1 (en) * 2021-04-05 2022-10-13 Veru Inc. Methods of treating inflammation
CN119212696A (zh) * 2022-04-28 2024-12-27 维鲁公司 [2-(1h-吲哚-3-基)-1h-咪唑-4-基](3,4,5-三甲氧基)甲酮和其盐的多晶型物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9029408B2 (en) * 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
US8822513B2 (en) * 2010-03-01 2014-09-02 Gtx, Inc. Compounds for treatment of cancer
US9447049B2 (en) * 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
MX2010014066A (es) * 2008-06-16 2011-06-01 Univ Tennessee Res Foundation Compuestos para el tratamiento del cancer.
JP5879273B2 (ja) * 2010-03-01 2016-03-08 ジーティーエックス・インコーポレイテッド 癌を処置するための化合物
JP5997156B2 (ja) * 2010-08-24 2016-09-28 ジーティーエックス・インコーポレイテッド 癌の治療のための化合物
CN105163584B (zh) * 2013-03-05 2019-06-04 田纳西大学研究基金会 用于治疗癌症的化合物

Also Published As

Publication number Publication date
EP3793548A4 (en) 2022-03-09
AU2019270091A1 (en) 2020-12-24
WO2019222392A1 (en) 2019-11-21
EP3793548A1 (en) 2021-03-24
KR20210021982A (ko) 2021-03-02
CN112437664A (zh) 2021-03-02
JP2021523915A (ja) 2021-09-09
CA3099922A1 (en) 2019-11-21
US20190374512A1 (en) 2019-12-12

Similar Documents

Publication Publication Date Title
MX2023000410A (es) Analogos de rapamicina como inhibidores de mtor.
ZA202003176B (en) Compounds useful as kinase inhibitors
MX2023000025A (es) Inhibidores de la quinasa progenitora hematopoyética 1 y usos de estos.
ZA201906111B (en) Cyclic di-nucleotides compounds for the treatment of cancer
PH12018502102A1 (en) Pyrrolotriazine compounds as tam inhibitors
MX2022005827A (es) Derivados de pirazol como inhibidores de malt1.
PH12018500587A1 (en) Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer
ZA202001717B (en) Compounds, salts thereof and methods for treatment of diseases
MX2020012291A (es) Compuestos para el tratamiento de cancer de mama triple negativo y cancer de ovario.
MX2017012730A (es) Inhibidores de indolamina 2,3-dioxigenasa (ido) para el tratamiento de cancer.
PH12018500268A1 (en) 2-amino-3-fluoro-3-(fluoromethyl)-6-methyl-6-phenyl-3,4,5,6-tetrahydropyridins as bace1 inhibitors
PH12020551390A1 (en) AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS
NZ759764A (en) Glucuronide prodrugs of janus kinase inhibitors
NZ761519A (en) Nlrp3 modulators
PH12021553132A1 (en) Methods of using rad51 inhibitors for treatment of pancreatic cancer
EA202090414A1 (ru) Соединения и их применение
PH12017501879A1 (en) Methods for treating cancer
PH12022550491A1 (en) Perk inhibiting pyrrolopyrimidine compounds
PH12022550497A1 (en) Perk inhibiting compounds
MX2020012281A (es) Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas.
EA201690763A1 (ru) Лечение рака поджелудочной железы
MX2020012292A (es) Compuestos para el tratamiento de cáncer de pancreas.
IL289201A (en) Compounds for the treatment of cancer
MX380776B (es) Derivados de pirazolilaminobenzimidazol como inhibidores de jak.
EA202192640A1 (ru) Хинолиновые производные и их применение для лечения рака